Search

Displaying results 2431 - 2440 of 6951 in total
  1. Drug

    Moclobemide

    go.drugbank.com/drugs/DB01171
    ApprovedInvestigational

    A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.

    Categories: Antidepressive Agents Indicated for Depression, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.

  3. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. … As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28].

  4. Drug

    Levocetirizine

    go.drugbank.com/drugs/DB06282
    ApprovedInvestigational

    [L7694] Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]

    Categories: Antihistamines for Systemic Use
  5. Drug

    Ramipril

    go.drugbank.com/drugs/DB00178
    ApprovedInvestigational

    Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

    Categories: Antihypertensive Agents Indicated for Hypertension
  6. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Previously, this drug was indicated only for patients with 17p gene deletion [F2130]. … A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one

  7. Drug

    Cyd dengue virus serotype 4 live (attenuated) antigen

    go.drugbank.com/drugs/DB15524
    ApprovedInvestigationalWithdrawn

    Mixtures: DENGVAXIA MD, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION, DENGVAXIA, POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION
  8. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

  9. Drug

    Sodium molybdate

    go.drugbank.com/drugs/DB14496
    Approved

    Mixtures: Addaven Concentrate for Solution for Infusion, ADDAVEN CONCENTRATE FOR SOLUTION FOR INFUSION
  10. Drug

    Albumin Aggregated

    go.drugbank.com/drugs/DB14230
    Approved

    Albumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection. … [L12816] This imaging agent is used to assess lung perfusion and for the evaluation of peritoneovenous (LeVeen) shunt patency.